

Review Form 1.6

Journal Name:	Journal of Pharmaceutical Research International
Manuscript Number:	Ms_JPRI_85192
Title of the Manuscript:	A Phase II Open-Label Multi-center Trial of Isotoxic Hypofractionated Radiotherapy for NSCLC
Type of the Article	Study Protocol

General guideline for Peer Review process:

This journal's peer review policy states that **NO** manuscript should be rejected only on the basis of '**lack of Novelty**', provided the manuscript is scientifically robust and technically sound. To know the complete guideline for Peer Review process, reviewers are requested to visit this link:

(<https://www.journalipri.com/index.php/JPRI/editorial-policy>)

PART 1: Review Comments

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
Compulsory REVISION comments		
Minor REVISION comments	Minor corrections as mentioned Use of future tense while explaining study design	agreed and modified the manuscript
Optional/General comments	Following references should be use for the study Bainbridge H, Dunlop A, McQuaid D, Gulliford S, Gunapala R, Ahmed M, Locke I, Nill S, Oelfke U, McDonald F. A comparison of isotoxic dose-escalated radiotherapy in lung cancer with moderate deep inspiration breath hold, mid-ventilation and internal target volume techniques. Clinical Oncology. 2022 Mar 1;34(3):151-9. Bouchart C, Engelholm JL, Closset J, Navez J, Loi P, Gökburun Y, De Grez T, Mans L, Hendlisz A, Bali MA, Eisendrath P. Isotoxic high-dose stereotactic body radiotherapy integrated in a total multimodal neoadjuvant strategy for the treatment of localized pancreatic ductal adenocarcinoma. Therapeutic Advances in Medical Oncology. 2021 Oct;13:17588359211045860.	agreed and modified the manuscript

PART 2:

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
Are there ethical issues in this manuscript?	<u>(If yes, Kindly please write down the ethical issues here in details)</u>	1. This trial was approved by the research ethics committee of the second hospital of Hebei Medical University (2018-R099). 2. Radiotherapy is the standard treatment for lung cancer.